[A19-01] Nivolumab (melanoma) -Addendum to Commission A18-53
Last updated 21.03.2019
Project no.:
A19-01
Commission:
Commission awarded on 07.01.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
Stage IIIB/C and IV disease: now hint of non-quantifiable added benefit. Stage IIIA disease: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-53 | Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-02-21 A G-BA decision was published.